BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
1.615
+0.015 (0.94%)
Jul 11, 2025, 9:42 AM - Market open
BioRestorative Therapies Employees
BioRestorative Therapies had 11 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
11
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$35,545
Profits / Employee
-$1,099,630
Market Cap
12.12M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
BRTX News
- 23 days ago - BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates - GlobeNewsWire
- 24 days ago - BioRestorative Announces Share Repurchase Program - GlobeNewsWire
- 4 weeks ago - BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease - GlobeNewsWire
- 4 weeks ago - BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025 - GlobeNewsWire
- 2 months ago - BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data - GlobeNewsWire
- 2 months ago - BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025 - GlobeNewsWire
- 2 months ago - BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025 - GlobeNewsWire